Contraindicated (1)bortezomib will improve the amount or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors could maximize mavacamten systemic publicity, leading to coronary heart failure as a consequence of systolic dysfunction. elvitegravir/cobicistat/emtricitabine/tenofovir DF improves levels of bortezomib by ... https://sr1866255321.blog2news.com/27288690/not-known-facts-about-anisperimus